Feb 22 2022

Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually

By |2022-02-21T18:59:51-05:00February 22nd, 2022|Featured, Investor News, Medical, News, Press Releases|1 Comment

Jackson Center, PA, February 22, 2022 – Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases.  With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens.  See Table Below.  This could lead to ...

Feb 8 2022

Halberd Eliminates 100% of Tau Protein From CSF – The 9th of 10 Target Neurodegenerative Disease Antigens

By |2022-02-07T18:58:11-05:00February 8th, 2022|Featured, Investor News, News|0 Comments

Tau buildup in the brain is linked to Alzheimer’s and other neurodegenerative diseases. Jackson Center, PA, February 8, 2022 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to eliminate 100% of Tau protein from cerebral spinal fluid (CSF) in less than 20 minutes with its patented extracorporeal laser exposure process.  Excess Tau in CSF ...

Dec 20 2021

Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases

By |2021-12-19T18:05:14-05:00December 20th, 2021|Investor News, Medical, News|0 Comments

Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid Jackson Center, PA, December 20, 2021 – Halberd Corporation (OTC PINK:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Halberd has also completed confirmatory tests on the elimination of all the previously tested cytokines (see table below).  Interleukin-2 ...

Dec 15 2021

Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases

By |2021-12-14T20:33:30-05:00December 15th, 2021|Investor News, Medical, News|0 Comments

Jackson Center, PA, December 15, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Interleukin-12 is a pro-inflammatory cytokine which has recently been identified at elevated levels in patients with Alzheimer’s Disease or mild cognitive impairment.  Halberd’s demonstrated ability to control the ...

Dec 6 2021

Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer’s Disease and PTSD/CTE

By |2021-12-05T19:03:46-05:00December 6th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, December 6, 2021 – Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF).  These tests confirmed virtually 100% elimination of TNF-alpha through Halberd’s patented extracorporeal process, in combination with its patent-pending exposure to tuned laser irradiation.  TNF-alpha is an inflammatory cytokine ...

Nov 8 2021

Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves

By |2021-11-07T19:56:42-05:00November 8th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, November 8, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves.  Previously, Halberd filed a provisional patent application on this treatment method.  Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd’s ...

Nov 1 2021

Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease

By |2021-10-31T17:47:07-04:00November 1st, 2021|Featured, Investor News, Medical, News|0 Comments

Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer’s Disease. Jackson Center, PA, November 1, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through its patented extracorporeal process in combination with its patent-pending laser eradication ...

Sep 13 2021

Halberd’s Treatment Eradicates Primary Building Block of Alzheimer’s Disease

By |2021-09-12T21:20:30-04:00September 13th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 13, 2021 – Halberd Corporation (OTC PINK:HALB) has successfully eradicated the primary building block of neurofibrillary tangles of Alzheimer’s Disease from test fluids in laboratory testing.  Through its patented extracorporeal process in combination with its patent-pending laser eradication process, replication tests conducted at Youngstown State University (YSU) achieved virtually 100% elimination ...

Aug 16 2021

Halberd’s Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN

By |2021-08-15T14:11:44-04:00August 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 16, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") research at Youngstown State University (YSU) caught the attention of Youngstown, OH TV news station, WKBN, a CBS affiliate. The station’s 5:00PM newscast on Friday, August 13, 2021, included a segment on Halberd’s on-going research and testing of its groundbreaking, patent protected technology at ...

Jul 28 2021

Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept – “Never Before Accomplished”

By |2021-07-27T17:35:26-04:00July 28th, 2021|Featured, Investor News, News|0 Comments

A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer’s Disease/PTSD/CTE Jackson Center, PA, July 28, 2021 – Halberd Corporation (OTC-PINK: "HALB") establishes “proof of concept” taking a major step towards the elimination of multiple infectious diseases, such as, malaria, tuberculosis, sepsis, meningitis, and pandemics, among others, by successfully eliminating ...

Go to Top